Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Sichuan Kelun Pharmaceutical (002422 CH)
Watchlist
75
Analysis
Health Care
•
China
Sichuan Kelun Pharmaceutical Co., Ltd. manufactures pharmaceutical products. The Company's products include large infusion products, tablets, capsules, antibiotic injection, lyophilized powder for injection, and traditional Chinese medicine.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Tencent
•
04 May 2024 00:35
Upgrading Emerging Markets to Market Weight; China/Hong Kong Continue to Bottom; Energy Breakdowns
Upgrading Emerging Markets $EEM $VWO to Market Weight; China/Hong Kong Continue to Bottom $FXI $MCHI $KWEB; Lows Likely in on $ACWI; Commodities...
Vermilion Research
Follow
404 Views
Share
bullish
•
Quantitative Analysis
•
28 Apr 2024 10:05
Northbound Flows (Apr 26th): CMB, Moutai, Ping An Insurance, Wuliangye, CATL, Mindray, Luxshare
We analyzed northbound Shanghai/Shenzhen connect flows in the past week and highlight flows for CMB, Moutai, Ping An Insurance, Wuliangye, CATL,...
Ke Yan, CFA, FRM
Follow
310 Views
Share
bearish
•
The United Laboratories International Holdings Limited
•
19 Sep 2023 12:21
United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable
United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have...
Xinyao (Criss) Wang
Follow
443 Views
Share
bullish
•
Innovent Biologics Inc
•
11 Sep 2023 21:11
Innovent Biologics Placement - Has Ample Cash but the Discount Is Enticing
Innovent Biologics Inc (1801 HK) (IB) aims to raise around US$313m for R&D and marketing. In this note, we talk about the deal dynamics and run the...
Sumeet Singh
Follow
500 Views
Share
bearish
•
Zai Lab
•
11 Sep 2023 09:16
Zai Lab (9688.HK/ZLAB.US) 2022/2023Q1 - The True Colors and the Risks Behind
In the insight, we analyzed major investment logic flaws of Zai Lab. As we expected, the company's performance is not ideal. The license-in model...
Xinyao (Criss) Wang
Follow
552 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.32.0
x